Horizon Therapeutics price target raised to $90 | HZNP Message Board Posts

Horizon Pharma, Inc.

  HZNP website

HZNP   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1877 of 1893  at  7/22/2020 10:04:23 AM  by

drugfree


Horizon Therapeutics price target raised to $90

This was found on "The Fly" July 22:
"Horizon Therapeutics price target raised to $90 from $61 at Piper Sandler 06:03 HZNP Piper Sandler analyst David Amsellem raised the firm's price target on Horizon Therapeutics to $90 from $61 and reiterates an Overweight rating on the shares. The analyst conducted a survey of 25 physicians who are current users of Horizon's Tepezza to gauge the extent to which adoption among physicians who currently use the product in patients with moderate-to-severely active thyroid eye disease will grow over time. The feedback points to "deep penetration" of Tepezza among active thyroid eye disease patients, Amsellem tells investors in a research note. The feedback also points to an "emerging physician audience" in patients with inactive disease, says the analyst. The checks reinforce his view that Tepezza has the makings of a multi-billion dollar franchise."

I think we all know what an analyst target of $90 means. Probably worth $120 to an acquirer. Just my opinion. Smoke 'em if you got 'em. GL longs.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 141
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1878 Re: Horizon Therapeutics price target raised to $90 geringerart 0 7/22/2020 12:54:50 PM






Financial Market Data provided by
.


Loading...